Newsletter Tool

Today’s Big News

Nov 18, 2024

CSL Behring shuts down California cell and gene therapy R&D site amid group pivot

Novartis, Ratio sign radiopharmaceutical pact to the tune of $745M biobucks

2024's Fiercest Women in Life Sciences

Neurogene rethinks gene therapy trial after high dose leaves Rett patient in critical condition

Intellia's CRISPR and Alnylam's RNAi data drops present contrasting visions for cardiomyopathy care

Trogenix unveils odyssey to find one-time tumor drugs with 'unprecedented selectivity'

Featured

CSL Behring shuts down California cell and gene therapy R&D site amid group pivot

By Angus Liu

CSL Behring is shutting down its U.S. R&D hub for cell and gene therapy in Pasadena, California, Fierce Biotech has learned.

Novartis, Ratio sign radiopharmaceutical pact to the tune of $745M biobucks

By Gabrielle Masson

Novartis is adding another radiopharmaceutical program to its collection, penning a deal worth $745 million in biobucks for rights to a cancer candidate from Ratio Therapeutics.

2024's Fiercest Women in Life Sciences

By Andrea Park

Despite lingering barriers to equity, women continue to do incredible, groundbreaking work throughout pharma, biotech and medtech. As seen in the following profiles of 10 of the fiercest women in life sciences, they’re spearheading Big Pharma business development, guiding up-and-coming biotechs and leading clinical research into potentially lifesaving technologies and therapeutics.

MRD Takes Center Stage: Accelerating Drug Approvals for Multiple Myeloma

Sponsored by Adaptive Biotechnologies

Discover how minimal residual disease (MRD) assessment is accelerating multiple myeloma drug development through FDA's latest guidance.

Neurogene rethinks gene therapy trial after high dose leaves Rett patient in critical condition

By Nick Paul Taylor

Neurogene has dropped plans to keep studying the high dose of its Rett syndrome gene therapy because of an adverse event that has left a patient in critical condition. The discontinuation has pushed back the anticipated completion of enrollment in the low-dose cohort.

Intellia's CRISPR and Alnylam's RNAi data drops present contrasting visions for cardiomyopathy care

By Nick Paul Taylor

Disease markers stabilized or improved in cardiomyopathy patients who received a single dose of Intellia Therapeutics’ in vivo CRISPR therapy in a phase 1 trial. But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its next-generation prospect.

Trogenix unveils odyssey to find one-time tumor drugs with 'unprecedented selectivity'

By James Waldron

A spinout from the University of Edinburgh in Scotland is armed with 15 million pounds ($19 million) in seed funding as the newly unveiled biotech continues its mission to find one-time cancer treatments.

Eisai sunsets development, access program for withdrawn obesity med in Dravet syndrome

By Fraiser Kansteiner

Eisai has terminated a phase 3 study of lorcaserin as a potential adjunct treatment for patients with Dravet syndrome, a rare form of epilepsy that starts in infancy. The company is also shutting down an extended access program in which patients were able to access the medication off-label.

Innate Pharma antibody pits natural killer cells against cancerous B cells in mice and monkeys

By Darren Incorvaia

French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma. The company’s tetraspecific antibody controlled tumors and improved survival in mice and reduced cancerous B cells in cynomolgus macaques.

Amid Seattle downsizing, Gilead cuts 100+ positions at California HQ

By Eric Sagonowsky

The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is planning more than 100 cuts at its corporate headquarters.

Planned Parenthood, nonprofits condemn executive power granted in looming House bill

By Noah Tong

Civil liberty organizations are sounding the alarm on a bill lawmakers are trying to push through during the lame duck session. They say it will give any presidential administration unchecked power to devastate nonprofit groups that are not ideologically aligned.

Fierce podcasts

Don’t miss an episode

Misconduct and the future of neurodegenerative disease research

This week on "The Top Line," we explore a neuroscientist's alleged misconduct and its impact on the future of neurodegenerative disease research.

Closing gaps in clinical trial infrastructure

Dig into this year’s Fierce Biotech Graveyard, layoff numbers

Resources

Whitepaper

Single Cell RNA Profiling FFPE Tissue

Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence.

Straight to Market in an Autoinjector

The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors.

Presented by Lonza

Whitepaper

7 “Make or Break” Factors for Emerging Biopharma Companies

This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.

Intensified Biomanufacturing

Unlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game!

Sponsored by: Syngene International Ltd.

Whitepaper

Planning for success in cell-based manufacturing

Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes.

Presented by: Thermo Fisher Scientific